Multimodal intervention benefits: Responder analysis of J-MINT PRIME Kanagawa trial.

Arch Gerontol GeriatrMay 5, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Yuhei Chiba, Keiko Ide, Shoko Suzuki et al.

✦ AI-curated · Sources linked

In 30 seconds

The J-MINT PRIME Kanagawa trial, a randomized controlled trial, explored a multimodal intervention for dementia prevention in 188 older adults. Although the primary analysis showed no significant benefits, a responder analysis identified a 'Target Group' of 108 participants who had an MMSE score < 28. In this group, the intervention significantly preserved MMSE trajectories compared to controls (P = 0.022).

Key findings

  • The 'Target Group' had an MMSE score < 28 or specific metabolic ranges.
  • In the Target Group, the intervention preserved MMSE trajectories compared to controls (P = 0.022).
  • The Non-Target Group, with MMSE ≥ 28, showed no significant interaction over time.

Why it matters

Identifying responsive subpopulations for dementia prevention interventions can enhance the effectiveness of treatment strategies. This study highlights the importance of targeting specific groups to potentially improve cognitive outcomes.

Source

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.